HRP20231730T1 - Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene - Google Patents
Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene Download PDFInfo
- Publication number
- HRP20231730T1 HRP20231730T1 HRP20231730TT HRP20231730T HRP20231730T1 HR P20231730 T1 HRP20231730 T1 HR P20231730T1 HR P20231730T T HRP20231730T T HR P20231730TT HR P20231730 T HRP20231730 T HR P20231730T HR P20231730 T1 HRP20231730 T1 HR P20231730T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- propyl
- phenyl
- pyrimidin
- trifluoromethyl
- Prior art date
Links
- -1 Phenylaminopyrimidine amide Chemical class 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 2
- 239000012822 autophagy inhibitor Substances 0.000 title 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 14
- 239000011737 fluorine Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 150000003951 lactams Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 239000012824 ERK inhibitor Substances 0.000 claims 4
- 229940124647 MEK inhibitor Drugs 0.000 claims 4
- 229940078123 Ras inhibitor Drugs 0.000 claims 4
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 2
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 claims 2
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 claims 2
- WUTVMXLIGHTZJC-OAQYLSRUSA-N 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Chemical compound N1=C(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)C(C)=CN=C1NC1=CC=C(F)C=C1Cl WUTVMXLIGHTZJC-OAQYLSRUSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- JNPRPMBJODOFEC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one Chemical compound CC1(N(C(C2=C1SC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)=O)CCN1CCOCC1)C JNPRPMBJODOFEC-UHFFFAOYSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 239000012624 DNA alkylating agent Substances 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- HHCBMISMPSAZBF-UHFFFAOYSA-N LY3009120 Chemical compound CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 claims 2
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims 2
- 229940124988 adagrasib Drugs 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229950003054 binimetinib Drugs 0.000 claims 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960002271 cobimetinib Drugs 0.000 claims 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 239000000138 intercalating agent Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 claims 2
- UEPXBTCUIIGYCY-UHFFFAOYSA-N n-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide Chemical compound C1=C(C=2C=C(N=C(OCCO)C=2)N2CCOCC2)C(C)=CC=C1NC(=O)C1=CC=NC(C(F)(F)F)=C1 UEPXBTCUIIGYCY-UHFFFAOYSA-N 0.000 claims 2
- FYNMINFUAIDIFL-UHFFFAOYSA-N n-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C(C(OC3CCOCC3)=NC=2)N2CCOCC2)C(C)=NC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 FYNMINFUAIDIFL-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
- AHRQYOSAXZQCIG-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=C=NC=N[CH]1 AHRQYOSAXZQCIG-UHFFFAOYSA-N 0.000 claims 2
- 229950007231 ravoxertinib Drugs 0.000 claims 2
- 229950010746 selumetinib Drugs 0.000 claims 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 2
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229950008878 ulixertinib Drugs 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- LMPDOXCWYUHPCS-UHFFFAOYSA-N BrC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F Chemical compound BrC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F LMPDOXCWYUHPCS-UHFFFAOYSA-N 0.000 claims 1
- IVVUWPRBZWNDMI-UHFFFAOYSA-N BrC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound BrC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IVVUWPRBZWNDMI-UHFFFAOYSA-N 0.000 claims 1
- APGVFTPJXNRPBQ-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1C(CCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1C(CCCC1)=O APGVFTPJXNRPBQ-UHFFFAOYSA-N 0.000 claims 1
- PKSYHDSAAWPLIW-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1C(COCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1C(COCCC1)=O PKSYHDSAAWPLIW-UHFFFAOYSA-N 0.000 claims 1
- UAYYKZZNHMUEOG-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1CCOCCC1=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C(C)C)NCCCN1CCOCCC1=O UAYYKZZNHMUEOG-UHFFFAOYSA-N 0.000 claims 1
- FZIKMSRWQIHEPR-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(CCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(CCCC1)=O FZIKMSRWQIHEPR-UHFFFAOYSA-N 0.000 claims 1
- PISBIRQDSAAKOZ-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(COCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(COCCC1)=O PISBIRQDSAAKOZ-UHFFFAOYSA-N 0.000 claims 1
- CQOFBAUFYMEUJH-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(OCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(OCCC1)=O CQOFBAUFYMEUJH-UHFFFAOYSA-N 0.000 claims 1
- UJMDMUHVWAZOTR-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O UJMDMUHVWAZOTR-UHFFFAOYSA-N 0.000 claims 1
- JKZCJRWCBDWFSQ-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CCCC1)=O JKZCJRWCBDWFSQ-UHFFFAOYSA-N 0.000 claims 1
- JJNYGRQUNOTHKX-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O JJNYGRQUNOTHKX-UHFFFAOYSA-N 0.000 claims 1
- WOLCMWYVWREPIC-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O WOLCMWYVWREPIC-UHFFFAOYSA-N 0.000 claims 1
- FGLYXMKXSPABBS-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O FGLYXMKXSPABBS-UHFFFAOYSA-N 0.000 claims 1
- MJOSHSOSEKCRIK-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)C(C)C)NCCCN1C(CCCC1)=O Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)C(C)C)NCCCN1C(CCCC1)=O MJOSHSOSEKCRIK-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- AWTXRQIPUKYCNI-UHFFFAOYSA-N C(#C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(#C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F AWTXRQIPUKYCNI-UHFFFAOYSA-N 0.000 claims 1
- AWTXRQIPUKYCNI-MICDWDOJSA-N C(#C[2H])C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(#C[2H])C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F AWTXRQIPUKYCNI-MICDWDOJSA-N 0.000 claims 1
- CNBTYICEJGEABG-WNWXXORZSA-N C(C([2H])([2H])[2H])(C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)([2H])[2H] Chemical compound C(C([2H])([2H])[2H])(C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)([2H])[2H] CNBTYICEJGEABG-WNWXXORZSA-N 0.000 claims 1
- IFTADVYEOSNWMG-UHFFFAOYSA-N C(C)(=O)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C1CC1 Chemical compound C(C)(=O)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C1CC1 IFTADVYEOSNWMG-UHFFFAOYSA-N 0.000 claims 1
- CLBLETGGLZIYFK-UHFFFAOYSA-N C(C)(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F CLBLETGGLZIYFK-UHFFFAOYSA-N 0.000 claims 1
- IKNSKZZGFRNHRX-UHFFFAOYSA-N C(C)(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C Chemical compound C(C)(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C IKNSKZZGFRNHRX-UHFFFAOYSA-N 0.000 claims 1
- ZJNLOQLSMMQJCA-UHFFFAOYSA-N C(C)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F ZJNLOQLSMMQJCA-UHFFFAOYSA-N 0.000 claims 1
- BZSDVQVTBOFJLL-UHFFFAOYSA-N C(C)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F BZSDVQVTBOFJLL-UHFFFAOYSA-N 0.000 claims 1
- QWWACCFMEXRJNA-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F QWWACCFMEXRJNA-UHFFFAOYSA-N 0.000 claims 1
- VACUNWJXQWSULQ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)C(C)(C)N1CCCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)C(C)(C)N1CCCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F VACUNWJXQWSULQ-UHFFFAOYSA-N 0.000 claims 1
- SKGXRBLEQBGWOM-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)C1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)C1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F SKGXRBLEQBGWOM-UHFFFAOYSA-N 0.000 claims 1
- PABNFAIPCWGBRA-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)C1CN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)C1CN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F PABNFAIPCWGBRA-UHFFFAOYSA-N 0.000 claims 1
- LNMCGIKEUIAVPM-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)CC(=O)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)CC(=O)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F LNMCGIKEUIAVPM-UHFFFAOYSA-N 0.000 claims 1
- SDGPVLWFFUEHQQ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)CCN1CCCC1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)CCN1CCCC1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F SDGPVLWFFUEHQQ-UHFFFAOYSA-N 0.000 claims 1
- MDOXMEPZQWOVBO-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)CCN1CCCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)CCN1CCCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F MDOXMEPZQWOVBO-UHFFFAOYSA-N 0.000 claims 1
- QRHCAXJCPIQXSJ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C(CN(CC1)C)=O)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C(CN(CC1)C)=O)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F QRHCAXJCPIQXSJ-UHFFFAOYSA-N 0.000 claims 1
- AJAMKMMSZZBZDR-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F AJAMKMMSZZBZDR-UHFFFAOYSA-N 0.000 claims 1
- DUIPFFCYLOHIJU-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F DUIPFFCYLOHIJU-UHFFFAOYSA-N 0.000 claims 1
- RLHWMDLZHBAKQU-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(CCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(CCC1)=O)C(F)(F)F RLHWMDLZHBAKQU-UHFFFAOYSA-N 0.000 claims 1
- VZAHFHRMKMTPQP-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F VZAHFHRMKMTPQP-UHFFFAOYSA-N 0.000 claims 1
- BSXYTYWKXLZGTQ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1C2CN(CC1CCC2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C2CN(CC1CCC2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F BSXYTYWKXLZGTQ-UHFFFAOYSA-N 0.000 claims 1
- GGBPYXXLHFNNQH-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC(N(C(C1)(C)C)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC(N(C(C1)(C)C)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F GGBPYXXLHFNNQH-UHFFFAOYSA-N 0.000 claims 1
- AAINBZSAIZTMON-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC(N(CC1)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC(N(CC1)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F AAINBZSAIZTMON-UHFFFAOYSA-N 0.000 claims 1
- LFQJKVPGGPYNBS-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC(NC(C1)(C)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC(NC(C1)(C)C)(C)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F LFQJKVPGGPYNBS-UHFFFAOYSA-N 0.000 claims 1
- CQSJFBDNXUVOOM-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC2CCCC(C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC2CCCC(C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F CQSJFBDNXUVOOM-UHFFFAOYSA-N 0.000 claims 1
- HPDVMFIKDUZYHB-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F HPDVMFIKDUZYHB-UHFFFAOYSA-N 0.000 claims 1
- OPGMUZWRDKDTCU-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F OPGMUZWRDKDTCU-UHFFFAOYSA-N 0.000 claims 1
- YVHQRJPJKCGINW-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F YVHQRJPJKCGINW-UHFFFAOYSA-N 0.000 claims 1
- WLURFGISFAFSLV-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F WLURFGISFAFSLV-UHFFFAOYSA-N 0.000 claims 1
- IHKWEEYZYZZOLA-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F IHKWEEYZYZZOLA-UHFFFAOYSA-N 0.000 claims 1
- LFTSVDSDFLWYET-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F LFTSVDSDFLWYET-UHFFFAOYSA-N 0.000 claims 1
- KNNMRFJCUQMYTK-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(C(OCCC1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(C(OCCC1)(C)C)=O)C(F)(F)F KNNMRFJCUQMYTK-UHFFFAOYSA-N 0.000 claims 1
- VUCUGYSYNXMAPN-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F VUCUGYSYNXMAPN-UHFFFAOYSA-N 0.000 claims 1
- UUASGXCMXHIZNI-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F UUASGXCMXHIZNI-UHFFFAOYSA-N 0.000 claims 1
- OPUVLAGAZGDDTR-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)(F)F OPUVLAGAZGDDTR-UHFFFAOYSA-N 0.000 claims 1
- ZYAAIAFEAUFLQB-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C#N ZYAAIAFEAUFLQB-UHFFFAOYSA-N 0.000 claims 1
- MJRDMMXBGIWZOG-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F MJRDMMXBGIWZOG-UHFFFAOYSA-N 0.000 claims 1
- VXHBVBKINDWEHT-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C#N VXHBVBKINDWEHT-UHFFFAOYSA-N 0.000 claims 1
- SUWLKNWJEOFKNA-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C#N SUWLKNWJEOFKNA-UHFFFAOYSA-N 0.000 claims 1
- TYESOCURWVQCGU-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)(F)F TYESOCURWVQCGU-UHFFFAOYSA-N 0.000 claims 1
- UHENJYQJDCQNQQ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N UHENJYQJDCQNQQ-UHFFFAOYSA-N 0.000 claims 1
- ZMHYFZVYOJWWOE-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C#N ZMHYFZVYOJWWOE-UHFFFAOYSA-N 0.000 claims 1
- WNZRMJFCJNTUIO-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F WNZRMJFCJNTUIO-UHFFFAOYSA-N 0.000 claims 1
- XYEQEIRMNYEHIP-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)(F)F XYEQEIRMNYEHIP-UHFFFAOYSA-N 0.000 claims 1
- XLKDYNNJOGJBPP-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)(F)F XLKDYNNJOGJBPP-UHFFFAOYSA-N 0.000 claims 1
- VNKMYOLQAJAEKP-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCC2(CC2)C1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCC2(CC2)C1=O)C(F)(F)F VNKMYOLQAJAEKP-UHFFFAOYSA-N 0.000 claims 1
- PAVRJIBMYLMTKI-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C#N PAVRJIBMYLMTKI-UHFFFAOYSA-N 0.000 claims 1
- CNBTYICEJGEABG-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F CNBTYICEJGEABG-UHFFFAOYSA-N 0.000 claims 1
- RLNPALQLCJAIAE-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CC1)CC)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CC1)CC)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F RLNPALQLCJAIAE-UHFFFAOYSA-N 0.000 claims 1
- RRYJYVXNFOMJHS-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F RRYJYVXNFOMJHS-UHFFFAOYSA-N 0.000 claims 1
- PFIONLBLDHFINT-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F PFIONLBLDHFINT-UHFFFAOYSA-N 0.000 claims 1
- AOZXEVBZUFVPRF-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F AOZXEVBZUFVPRF-UHFFFAOYSA-N 0.000 claims 1
- SOTMOQPACMRFPT-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N SOTMOQPACMRFPT-UHFFFAOYSA-N 0.000 claims 1
- SXJSQUWFNAEEHQ-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F SXJSQUWFNAEEHQ-UHFFFAOYSA-N 0.000 claims 1
- CLWMOVYPHLSHDM-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F CLWMOVYPHLSHDM-UHFFFAOYSA-N 0.000 claims 1
- WSMVERRUSKFBQP-UHFFFAOYSA-N C(C)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F WSMVERRUSKFBQP-UHFFFAOYSA-N 0.000 claims 1
- MJMFMAXWXXYSCV-HSZRJFAPSA-N C(C)C1=C(C=CC(=C1)N1C[C@@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N MJMFMAXWXXYSCV-HSZRJFAPSA-N 0.000 claims 1
- PVFORSQJOUCBHD-OYRHEFFESA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F PVFORSQJOUCBHD-OYRHEFFESA-N 0.000 claims 1
- BUIYCNBBNIZOMP-ZRZAMGCNSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(C(OCCC1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(C(OCCC1)(C)C)=O)C(F)(F)F BUIYCNBBNIZOMP-ZRZAMGCNSA-N 0.000 claims 1
- OMEZZFYHGIDKJO-BGYRXZFFSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F OMEZZFYHGIDKJO-BGYRXZFFSA-N 0.000 claims 1
- DCBNFPAMRMPNKJ-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F DCBNFPAMRMPNKJ-SZPZYZBQSA-N 0.000 claims 1
- ZYGWUWPATMKCGB-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F ZYGWUWPATMKCGB-SZPZYZBQSA-N 0.000 claims 1
- PGJWANNTCJWASC-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OC(CC1)(C)C)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OC(CC1)(C)C)=O)C(F)(F)F PGJWANNTCJWASC-SZPZYZBQSA-N 0.000 claims 1
- RTGCZCKWXXHVFF-ZRZAMGCNSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N RTGCZCKWXXHVFF-ZRZAMGCNSA-N 0.000 claims 1
- LOFVNIKOUNWELD-OYRHEFFESA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F LOFVNIKOUNWELD-OYRHEFFESA-N 0.000 claims 1
- MGDGIRDJVTUEAJ-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F MGDGIRDJVTUEAJ-SZPZYZBQSA-N 0.000 claims 1
- ONJQRCYYVMYVKG-ZRZAMGCNSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)(F)F ONJQRCYYVMYVKG-ZRZAMGCNSA-N 0.000 claims 1
- UJLZEWNBSUYYQU-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F UJLZEWNBSUYYQU-SZPZYZBQSA-N 0.000 claims 1
- MJMFMAXWXXYSCV-QHCPKHFHSA-N C(C)C1=C(C=CC(=C1)N1C[C@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1C[C@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N MJMFMAXWXXYSCV-QHCPKHFHSA-N 0.000 claims 1
- FPFSGHADYJWPCL-PMACEKPBSA-N C(C)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F FPFSGHADYJWPCL-PMACEKPBSA-N 0.000 claims 1
- OTDHUDSQVRUCDS-SFTDATJTSA-N C(C)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F OTDHUDSQVRUCDS-SFTDATJTSA-N 0.000 claims 1
- USYCICNCWLVGPA-SZPZYZBQSA-N C(C)C1=C(C=CC(=C1)N1[C@H]2CN(C[C@@H]1CC2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1[C@H]2CN(C[C@@H]1CC2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F USYCICNCWLVGPA-SZPZYZBQSA-N 0.000 claims 1
- GVQCZRGLBXDQBT-FGZHOGPDSA-N C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N GVQCZRGLBXDQBT-FGZHOGPDSA-N 0.000 claims 1
- FPFSGHADYJWPCL-WOJBJXKFSA-N C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F FPFSGHADYJWPCL-WOJBJXKFSA-N 0.000 claims 1
- OTDHUDSQVRUCDS-NHCUHLMSSA-N C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F OTDHUDSQVRUCDS-NHCUHLMSSA-N 0.000 claims 1
- ARGVKFVKRIQIJX-UHFFFAOYSA-N C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F ARGVKFVKRIQIJX-UHFFFAOYSA-N 0.000 claims 1
- NDTSOEQZPXJFKR-UHFFFAOYSA-N C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F NDTSOEQZPXJFKR-UHFFFAOYSA-N 0.000 claims 1
- FVPZFJQRJUIHCR-UHFFFAOYSA-N C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C(C)C1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F FVPZFJQRJUIHCR-UHFFFAOYSA-N 0.000 claims 1
- IOLAHBVLKGIGHA-SFHVURJKSA-N C(C)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1C[C@@H](CC1)C#N Chemical compound C(C)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1C[C@@H](CC1)C#N IOLAHBVLKGIGHA-SFHVURJKSA-N 0.000 claims 1
- IOLAHBVLKGIGHA-GOSISDBHSA-N C(C)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1C[C@H](CC1)C#N Chemical compound C(C)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1C[C@H](CC1)C#N IOLAHBVLKGIGHA-GOSISDBHSA-N 0.000 claims 1
- OWLBTUKATQEQEV-UHFFFAOYSA-N C(C)N(CCCC1=CC(=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F)C(F)(F)F)CC Chemical compound C(C)N(CCCC1=CC(=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F)C(F)(F)F)CC OWLBTUKATQEQEV-UHFFFAOYSA-N 0.000 claims 1
- SWEADQVYDCJMAP-UHFFFAOYSA-N C(C)N(CCCC1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC)CC Chemical compound C(C)N(CCCC1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC)CC SWEADQVYDCJMAP-UHFFFAOYSA-N 0.000 claims 1
- QLGZSVIPUWWUJH-UHFFFAOYSA-N C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C Chemical compound C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C QLGZSVIPUWWUJH-UHFFFAOYSA-N 0.000 claims 1
- IOHXTDIKGRCNIG-UHFFFAOYSA-N C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C(C)C Chemical compound C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C(C)C IOHXTDIKGRCNIG-UHFFFAOYSA-N 0.000 claims 1
- UZJNMSFOSVYFAF-UHFFFAOYSA-N C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F)C(C)C Chemical compound C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F)C(C)C UZJNMSFOSVYFAF-UHFFFAOYSA-N 0.000 claims 1
- VPQNZYLPPULCET-UHFFFAOYSA-N C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C(C)C Chemical compound C(C)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C(C)C VPQNZYLPPULCET-UHFFFAOYSA-N 0.000 claims 1
- YYVZPHQBYZMHAK-UHFFFAOYSA-N C(C)N1CCN(CCC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C(C)N1CCN(CCC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F YYVZPHQBYZMHAK-UHFFFAOYSA-N 0.000 claims 1
- UWHRWJLJEUPJCU-UHFFFAOYSA-N C1(CC1)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=C(C(=C1)N1CCN(CC1)C)F)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F UWHRWJLJEUPJCU-UHFFFAOYSA-N 0.000 claims 1
- QJJKSDRUVULRGA-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)CCCN1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)CCCN1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F QJJKSDRUVULRGA-UHFFFAOYSA-N 0.000 claims 1
- WAXWVUNMWTZPQX-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F WAXWVUNMWTZPQX-UHFFFAOYSA-N 0.000 claims 1
- UEVFRJUEUSJXSI-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)CN1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)CN1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F UEVFRJUEUSJXSI-UHFFFAOYSA-N 0.000 claims 1
- USEUIPWVXMYYNW-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)CN1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)CN1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F USEUIPWVXMYYNW-UHFFFAOYSA-N 0.000 claims 1
- NMNDYOHHJXHDJJ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)CN1CCS(CC1)(=O)=O)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)CN1CCS(CC1)(=O)=O)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F NMNDYOHHJXHDJJ-UHFFFAOYSA-N 0.000 claims 1
- RYCIBIKHSJTTOT-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C2CN(C(C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)F RYCIBIKHSJTTOT-UHFFFAOYSA-N 0.000 claims 1
- CFTILKTYJGSVLS-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CC(C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CC(C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F CFTILKTYJGSVLS-UHFFFAOYSA-N 0.000 claims 1
- IELLBDCSOYFERX-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CC(C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CC(C1)CN(C)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IELLBDCSOYFERX-UHFFFAOYSA-N 0.000 claims 1
- PEGMKYTYRZPTDZ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CC(N(C(C1)C)C)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CC(N(C(C1)C)C)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F PEGMKYTYRZPTDZ-UHFFFAOYSA-N 0.000 claims 1
- WMKSIOPIUWACJK-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CC2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F WMKSIOPIUWACJK-UHFFFAOYSA-N 0.000 claims 1
- NJXLTYGENUQJDF-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F NJXLTYGENUQJDF-UHFFFAOYSA-N 0.000 claims 1
- UDOYOHWENYBLJP-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F UDOYOHWENYBLJP-UHFFFAOYSA-N 0.000 claims 1
- TWCCWLZDQFAPEX-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F TWCCWLZDQFAPEX-UHFFFAOYSA-N 0.000 claims 1
- QDXRIPQHPGABEJ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCCC1)=O)C(F)(F)F QDXRIPQHPGABEJ-UHFFFAOYSA-N 0.000 claims 1
- SRZKHXNJVSLTAM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C#N SRZKHXNJVSLTAM-UHFFFAOYSA-N 0.000 claims 1
- RALVITCWCHUJDC-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)(F)F RALVITCWCHUJDC-UHFFFAOYSA-N 0.000 claims 1
- IVGLXBHAUMFOAX-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CN(CCC1)C)=O)C(F)F IVGLXBHAUMFOAX-UHFFFAOYSA-N 0.000 claims 1
- QHKKXNOWBDXXRL-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCC1)=O)C(F)(F)F QHKKXNOWBDXXRL-UHFFFAOYSA-N 0.000 claims 1
- CHOBNILKNMKMGQ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C#N CHOBNILKNMKMGQ-UHFFFAOYSA-N 0.000 claims 1
- WFJKFHRXWSKAGF-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F WFJKFHRXWSKAGF-UHFFFAOYSA-N 0.000 claims 1
- MQKVQMLTWRGVKI-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C#N MQKVQMLTWRGVKI-UHFFFAOYSA-N 0.000 claims 1
- OMJSTNNQGLHVPM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C(F)(F)F OMJSTNNQGLHVPM-UHFFFAOYSA-N 0.000 claims 1
- WKBXLJAQBJYOTN-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCC1)C)=O)C(F)F WKBXLJAQBJYOTN-UHFFFAOYSA-N 0.000 claims 1
- AUBZFHQGNRUYIQ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C#N AUBZFHQGNRUYIQ-UHFFFAOYSA-N 0.000 claims 1
- SIKUOACTMACVTF-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)(F)F SIKUOACTMACVTF-UHFFFAOYSA-N 0.000 claims 1
- SZJZYDSBSHQQOM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(N(CCCC1)C)=O)C(F)F SZJZYDSBSHQQOM-UHFFFAOYSA-N 0.000 claims 1
- VOBPQMLZQDHLFV-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OC(CC1)(C)C)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OC(CC1)(C)C)=O)C(F)(F)F VOBPQMLZQDHLFV-UHFFFAOYSA-N 0.000 claims 1
- UMOUGYTUABVZTB-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N UMOUGYTUABVZTB-UHFFFAOYSA-N 0.000 claims 1
- NUHKMVOFOMOXAT-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F NUHKMVOFOMOXAT-UHFFFAOYSA-N 0.000 claims 1
- WDTRCTNSANMIAZ-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C#N WDTRCTNSANMIAZ-UHFFFAOYSA-N 0.000 claims 1
- VTNOIVHOVHYRLM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)(F)F VTNOIVHOVHYRLM-UHFFFAOYSA-N 0.000 claims 1
- ULPHOUZUAPMYPA-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCCC1)=O)C(F)F ULPHOUZUAPMYPA-UHFFFAOYSA-N 0.000 claims 1
- UBYLDDMCWNCBSK-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C#N UBYLDDMCWNCBSK-UHFFFAOYSA-N 0.000 claims 1
- VKEFEFAAFPPBTE-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)(F)F VKEFEFAAFPPBTE-UHFFFAOYSA-N 0.000 claims 1
- ZIBSESZQHYMAOX-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCN(CCC1=O)C)C(F)F ZIBSESZQHYMAOX-UHFFFAOYSA-N 0.000 claims 1
- QKKJLOBEJHVITE-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C#N QKKJLOBEJHVITE-UHFFFAOYSA-N 0.000 claims 1
- GQUBPALRLOKRTI-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F GQUBPALRLOKRTI-UHFFFAOYSA-N 0.000 claims 1
- OINSRIFEWJJBBF-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)F OINSRIFEWJJBBF-UHFFFAOYSA-N 0.000 claims 1
- CBSLZLZJHDJMKM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)CC)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CC1)CC)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F CBSLZLZJHDJMKM-UHFFFAOYSA-N 0.000 claims 1
- SPSUMHLTCGCSLC-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCN(CCC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F SPSUMHLTCGCSLC-UHFFFAOYSA-N 0.000 claims 1
- LCWFZNKLFGJNJP-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F LCWFZNKLFGJNJP-UHFFFAOYSA-N 0.000 claims 1
- SEWZZCOEMMFAIM-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F SEWZZCOEMMFAIM-UHFFFAOYSA-N 0.000 claims 1
- DTGCHOAYIKSTGA-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N DTGCHOAYIKSTGA-UHFFFAOYSA-N 0.000 claims 1
- MQLFHKOGEJKXRK-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F MQLFHKOGEJKXRK-UHFFFAOYSA-N 0.000 claims 1
- SJUKHHUJPLADGE-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)F SJUKHHUJPLADGE-UHFFFAOYSA-N 0.000 claims 1
- MPBUKABZHBXLTC-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F MPBUKABZHBXLTC-UHFFFAOYSA-N 0.000 claims 1
- FSXMLPMNBPESPK-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F FSXMLPMNBPESPK-UHFFFAOYSA-N 0.000 claims 1
- CASQWRHASWVTIL-UHFFFAOYSA-N C1(CC1)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F CASQWRHASWVTIL-UHFFFAOYSA-N 0.000 claims 1
- YBORTFAHOSEYGL-JOCHJYFZSA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@@H]2N(CC1)CCC2)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F YBORTFAHOSEYGL-JOCHJYFZSA-N 0.000 claims 1
- HCWCHJOBYHDFDV-SZPZYZBQSA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F HCWCHJOBYHDFDV-SZPZYZBQSA-N 0.000 claims 1
- JCOGLVLJCXIDOP-SZPZYZBQSA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)F JCOGLVLJCXIDOP-SZPZYZBQSA-N 0.000 claims 1
- PVJOXEQNCJYCBA-ZRZAMGCNSA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C#N PVJOXEQNCJYCBA-ZRZAMGCNSA-N 0.000 claims 1
- VHIYNAVQGYVNPU-OYRHEFFESA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)F VHIYNAVQGYVNPU-OYRHEFFESA-N 0.000 claims 1
- JSQFYCJAWWXHMP-SZPZYZBQSA-N C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F JSQFYCJAWWXHMP-SZPZYZBQSA-N 0.000 claims 1
- PMZBINKPZKWPJR-PMACEKPBSA-N C1(CC1)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F PMZBINKPZKWPJR-PMACEKPBSA-N 0.000 claims 1
- IZMCMSMKLGSEQB-SFTDATJTSA-N C1(CC1)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IZMCMSMKLGSEQB-SFTDATJTSA-N 0.000 claims 1
- IZMCMSMKLGSEQB-NHCUHLMSSA-N C1(CC1)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IZMCMSMKLGSEQB-NHCUHLMSSA-N 0.000 claims 1
- YRMXQNIZUFGSCP-UHFFFAOYSA-N C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O Chemical compound C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O YRMXQNIZUFGSCP-UHFFFAOYSA-N 0.000 claims 1
- QPOIHHJVVWLARI-UHFFFAOYSA-N C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O Chemical compound C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O QPOIHHJVVWLARI-UHFFFAOYSA-N 0.000 claims 1
- GZTFTQWXWZCKDH-UHFFFAOYSA-N C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O Chemical compound C1(CC1)C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O GZTFTQWXWZCKDH-UHFFFAOYSA-N 0.000 claims 1
- KCVNZSBJMJYQEX-UHFFFAOYSA-N C1(CC1)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1CC(N(CC1)C)=O Chemical compound C1(CC1)C=1C=C(C=CC=1NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)N1CC(N(CC1)C)=O KCVNZSBJMJYQEX-UHFFFAOYSA-N 0.000 claims 1
- BIZNYXIVHTYNJN-UHFFFAOYSA-N C1(CCC1)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C Chemical compound C1(CCC1)N1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C BIZNYXIVHTYNJN-UHFFFAOYSA-N 0.000 claims 1
- PXQXFSQBRBBYQF-UHFFFAOYSA-N C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F)CCC2 Chemical compound C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F)CCC2 PXQXFSQBRBBYQF-UHFFFAOYSA-N 0.000 claims 1
- CUPRHFWYUMFFTO-UHFFFAOYSA-N C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F)CCCC2 Chemical compound C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F)CCCC2 CUPRHFWYUMFFTO-UHFFFAOYSA-N 0.000 claims 1
- RJGPFQSWHVZMLH-UHFFFAOYSA-N C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F)CCC2 Chemical compound C1C2N(CCN1C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F)CCC2 RJGPFQSWHVZMLH-UHFFFAOYSA-N 0.000 claims 1
- PCBFGKOYWWXHNH-UHFFFAOYSA-N CC(C#N)(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC(C#N)(C)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F PCBFGKOYWWXHNH-UHFFFAOYSA-N 0.000 claims 1
- SBOOTIXVAFEQJN-UHFFFAOYSA-N CC1(CN(CCN1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F)CC)C Chemical compound CC1(CN(CCN1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F)CC)C SBOOTIXVAFEQJN-UHFFFAOYSA-N 0.000 claims 1
- OSWANJYFJSHGLX-UHFFFAOYSA-N CC1=C(C=CC(=C1)C1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)C1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F OSWANJYFJSHGLX-UHFFFAOYSA-N 0.000 claims 1
- COYHQUFIRNOMHU-UHFFFAOYSA-N CC1=C(C=CC(=C1)C1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)C1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F COYHQUFIRNOMHU-UHFFFAOYSA-N 0.000 claims 1
- NHSRYMXZPJFWHA-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F NHSRYMXZPJFWHA-UHFFFAOYSA-N 0.000 claims 1
- MSEBLGSMDNWJKK-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F MSEBLGSMDNWJKK-UHFFFAOYSA-N 0.000 claims 1
- HGNSZMSXJHIFGT-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F HGNSZMSXJHIFGT-UHFFFAOYSA-N 0.000 claims 1
- XXGSCUPNCDZMMQ-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F XXGSCUPNCDZMMQ-UHFFFAOYSA-N 0.000 claims 1
- MOQGFNDTZIILMF-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCN(CC1)S(=O)(=O)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCN(CC1)S(=O)(=O)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F MOQGFNDTZIILMF-UHFFFAOYSA-N 0.000 claims 1
- SQUDJDFDLUBPNX-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F SQUDJDFDLUBPNX-UHFFFAOYSA-N 0.000 claims 1
- USEIIEZFEKLQIP-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F USEIIEZFEKLQIP-UHFFFAOYSA-N 0.000 claims 1
- LPFKTWRUOKEEDR-UHFFFAOYSA-N CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1CCNCC1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F LPFKTWRUOKEEDR-UHFFFAOYSA-N 0.000 claims 1
- KWCFNMWYHQFCHZ-OYRHEFFESA-N CC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F KWCFNMWYHQFCHZ-OYRHEFFESA-N 0.000 claims 1
- JPUSJPBRGOEPMF-OYRHEFFESA-N CC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F JPUSJPBRGOEPMF-OYRHEFFESA-N 0.000 claims 1
- NOBLYDDPNOSHGM-OALUTQOASA-N CC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F NOBLYDDPNOSHGM-OALUTQOASA-N 0.000 claims 1
- IBEWVVTYFYFXIK-PMACEKPBSA-N CC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IBEWVVTYFYFXIK-PMACEKPBSA-N 0.000 claims 1
- NOBLYDDPNOSHGM-RTBURBONSA-N CC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F NOBLYDDPNOSHGM-RTBURBONSA-N 0.000 claims 1
- IBEWVVTYFYFXIK-WOJBJXKFSA-N CC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F IBEWVVTYFYFXIK-WOJBJXKFSA-N 0.000 claims 1
- OJABVVDAYVVVBA-UHFFFAOYSA-N CC1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F OJABVVDAYVVVBA-UHFFFAOYSA-N 0.000 claims 1
- SXCXFTVUQPYNCV-UHFFFAOYSA-N CC1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=NC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F SXCXFTVUQPYNCV-UHFFFAOYSA-N 0.000 claims 1
- JINWPIFYYLDVRZ-UHFFFAOYSA-N CC1=C(C=NC(=C1)N1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=NC(=C1)N1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F JINWPIFYYLDVRZ-UHFFFAOYSA-N 0.000 claims 1
- VSOPZTDAUVTWRU-UHFFFAOYSA-N CC1=C(C=NC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CC1=C(C=NC(=C1)N1CCOCC1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F VSOPZTDAUVTWRU-UHFFFAOYSA-N 0.000 claims 1
- ATFNTYFBYKDQQJ-UHFFFAOYSA-N CN(C)CC1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC Chemical compound CN(C)CC1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC ATFNTYFBYKDQQJ-UHFFFAOYSA-N 0.000 claims 1
- JVQNSMUREDOPQJ-UHFFFAOYSA-N CN(C)CC1CN(C1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC Chemical compound CN(C)CC1CN(C1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC JVQNSMUREDOPQJ-UHFFFAOYSA-N 0.000 claims 1
- OUASZEXNIOBVSN-UHFFFAOYSA-N CN1C2CN(C(C1)C2)C1=CC=C(C=N1)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CN1C2CN(C(C1)C2)C1=CC=C(C=N1)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F OUASZEXNIOBVSN-UHFFFAOYSA-N 0.000 claims 1
- BDICWCZZWWYTGW-UHFFFAOYSA-N CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F)C(F)(F)F BDICWCZZWWYTGW-UHFFFAOYSA-N 0.000 claims 1
- PTHLGBYJXSHHMW-UHFFFAOYSA-N CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C(F)(F)F PTHLGBYJXSHHMW-UHFFFAOYSA-N 0.000 claims 1
- BAKXLGMKLMXSBD-UHFFFAOYSA-N CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC(F)(F)F Chemical compound CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC(F)(F)F BAKXLGMKLMXSBD-UHFFFAOYSA-N 0.000 claims 1
- GSPYHFPONRNSEZ-UHFFFAOYSA-N CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)OC(F)(F)F Chemical compound CN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)OC(F)(F)F GSPYHFPONRNSEZ-UHFFFAOYSA-N 0.000 claims 1
- UIGAYSWREICTEP-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F UIGAYSWREICTEP-UHFFFAOYSA-N 0.000 claims 1
- AEWJHLPALHPJBR-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(COCCC1)=O)C(F)(F)F AEWJHLPALHPJBR-UHFFFAOYSA-N 0.000 claims 1
- HDPYLRBNPLHGOD-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F HDPYLRBNPLHGOD-UHFFFAOYSA-N 0.000 claims 1
- OFXQIOCQGFOEIX-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(OCCCC1)=O)C(F)(F)F OFXQIOCQGFOEIX-UHFFFAOYSA-N 0.000 claims 1
- JGCPLXFYKCAKRX-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F JGCPLXFYKCAKRX-UHFFFAOYSA-N 0.000 claims 1
- HRYPRPPAWLOGFG-UHFFFAOYSA-N CN1CCN(CC1)C=1C=CC(=C(C#N)C=1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CN1CCN(CC1)C=1C=CC(=C(C#N)C=1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F HRYPRPPAWLOGFG-UHFFFAOYSA-N 0.000 claims 1
- RUEMLBORJODQDM-UHFFFAOYSA-N CN1CCN(CC1)C=1C=CC(=C(C=1)CC#N)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound CN1CCN(CC1)C=1C=CC(=C(C=1)CC#N)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F RUEMLBORJODQDM-UHFFFAOYSA-N 0.000 claims 1
- VHNQRCVDPCNRQK-UHFFFAOYSA-N CN1CCN(CC1)C=1C=CC(=NC=1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound CN1CCN(CC1)C=1C=CC(=NC=1)NC1=NC=C(C(=C1)NCCCN1C(CCCC1)=O)C(F)(F)F VHNQRCVDPCNRQK-UHFFFAOYSA-N 0.000 claims 1
- DAXDWHWKEIPTFG-ZRZAMGCNSA-N CN1[C@H]2CN(C[C@@H]1CC2)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(CCCCC1)=O)C(F)(F)F Chemical compound CN1[C@H]2CN(C[C@@H]1CC2)C1=CC=C(C=C1)NC1=NC=C(C(=C1)NCCCN1C(CCCCC1)=O)C(F)(F)F DAXDWHWKEIPTFG-ZRZAMGCNSA-N 0.000 claims 1
- OEMGYIVNIXFYHU-UHFFFAOYSA-N COC=1C=C(C(=O)NC2CCN(CC2)C)C=CC=1NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound COC=1C=C(C(=O)NC2CCN(CC2)C)C=CC=1NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F OEMGYIVNIXFYHU-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- JBZJXLMOTZFWNG-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CC(N(CC1)C)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1CC(N(CC1)C)C)NC1=NC=C(C(=C1)NCCCN1CCOCCC1=O)C(F)(F)F JBZJXLMOTZFWNG-UHFFFAOYSA-N 0.000 claims 1
- ZPBMGYDYHKLGHR-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CC(N(CC1)C)C)NC1=NC=C(C(=N1)NCCCN1C(CCCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1CC(N(CC1)C)C)NC1=NC=C(C(=N1)NCCCN1C(CCCCC1)=O)C(F)(F)F ZPBMGYDYHKLGHR-UHFFFAOYSA-N 0.000 claims 1
- FRPPRHKNXUWKSU-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F FRPPRHKNXUWKSU-UHFFFAOYSA-N 0.000 claims 1
- VZNQZJZAJBOEAF-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F VZNQZJZAJBOEAF-UHFFFAOYSA-N 0.000 claims 1
- AHXINAWLBZJMFX-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F AHXINAWLBZJMFX-UHFFFAOYSA-N 0.000 claims 1
- HPHIMHYBTSWFIN-KDURUIRLSA-N ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(COCCC1)=O)C(F)(F)F HPHIMHYBTSWFIN-KDURUIRLSA-N 0.000 claims 1
- NJNYFHHCLOJNRM-HDICACEKSA-N ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F NJNYFHHCLOJNRM-HDICACEKSA-N 0.000 claims 1
- YYXQWZAPYDVBTJ-KDURUIRLSA-N ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1C[C@H]2CC[C@@H](C1)N2C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F YYXQWZAPYDVBTJ-KDURUIRLSA-N 0.000 claims 1
- QQIAKFNSBGWJGU-IRXDYDNUSA-N ClC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F QQIAKFNSBGWJGU-IRXDYDNUSA-N 0.000 claims 1
- YAYGUYPCZMPVOH-ROUUACIJSA-N ClC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1[C@@H]2CN([C@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F YAYGUYPCZMPVOH-ROUUACIJSA-N 0.000 claims 1
- QQIAKFNSBGWJGU-IAGOWNOFSA-N ClC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1C(OCCC1)=O)C(F)(F)F QQIAKFNSBGWJGU-IAGOWNOFSA-N 0.000 claims 1
- YAYGUYPCZMPVOH-QZTJIDSGSA-N ClC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound ClC1=C(C=CC(=C1)N1[C@H]2CN([C@@H](C1)C2)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F YAYGUYPCZMPVOH-QZTJIDSGSA-N 0.000 claims 1
- KBDBMBHUANLPHD-UHFFFAOYSA-N ClC=1C(=CC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O Chemical compound ClC=1C(=CC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O KBDBMBHUANLPHD-UHFFFAOYSA-N 0.000 claims 1
- GUEQWUACKYXEFK-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCN(CC1)C)C)NCCCN1C(CCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCN(CC1)C)C)NCCCN1C(CCCC1)=O GUEQWUACKYXEFK-UHFFFAOYSA-N 0.000 claims 1
- JKYHOKHGVHUVGL-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCNCC1)C)NCCCN1C(CCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCNCC1)C)NCCCN1C(CCCC1)=O JKYHOKHGVHUVGL-UHFFFAOYSA-N 0.000 claims 1
- CAIQFVFPDWVKTR-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(CCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(CCCC1)=O CAIQFVFPDWVKTR-UHFFFAOYSA-N 0.000 claims 1
- QDQOYQKIXDDBKQ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(COCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1C(COCCC1)=O QDQOYQKIXDDBKQ-UHFFFAOYSA-N 0.000 claims 1
- MARRIYKJEZMYOI-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)C1CC1)NCCCN1CCOCCC1=O MARRIYKJEZMYOI-UHFFFAOYSA-N 0.000 claims 1
- OLWUGAGPZCFHRZ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CCCC1)=O OLWUGAGPZCFHRZ-UHFFFAOYSA-N 0.000 claims 1
- LRTDSHINTXQWDX-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCC1)=O LRTDSHINTXQWDX-UHFFFAOYSA-N 0.000 claims 1
- JDILKYULMBGXKZ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O JDILKYULMBGXKZ-UHFFFAOYSA-N 0.000 claims 1
- JYKWXRCDUIQDOB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)C(C)C)NCCCN1C(CCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)C(C)C)NCCCN1C(CCCC1)=O JYKWXRCDUIQDOB-UHFFFAOYSA-N 0.000 claims 1
- VMJUNEDPNNGLTK-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)C1CC1)NCCCN1CCOCCC1=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)C1CC1)NCCCN1CCOCCC1=O VMJUNEDPNNGLTK-UHFFFAOYSA-N 0.000 claims 1
- HOWYIXNKQCKXST-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)C1CC1)NCCCN1C(COCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)C1CC1)NCCCN1C(COCCC1)=O HOWYIXNKQCKXST-UHFFFAOYSA-N 0.000 claims 1
- JWLICZLKAMDCRM-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)CC)NCCCN1C(COCCC1)=O Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)CC)NCCCN1C(COCCC1)=O JWLICZLKAMDCRM-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- OONGBTUKDLESGJ-UHFFFAOYSA-N FC(C)(F)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F Chemical compound FC(C)(F)C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F OONGBTUKDLESGJ-UHFFFAOYSA-N 0.000 claims 1
- KSKQLJXJWHVGDA-UHFFFAOYSA-N FC(C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)F Chemical compound FC(C1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)F KSKQLJXJWHVGDA-UHFFFAOYSA-N 0.000 claims 1
- GSCSJYXAQABAFU-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C2CN(C(C1)C2)C)CC)NCCCN1C(COCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C2CN(C(C1)C2)C)CC)NCCCN1C(COCCC1)=O)F GSCSJYXAQABAFU-UHFFFAOYSA-N 0.000 claims 1
- FHWNZEYDXVZMMA-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C2CN(C(C1)C2)C)CC)NCCCN1CCOCCC1=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C2CN(C(C1)C2)C)CC)NCCCN1CCOCCC1=O)F FHWNZEYDXVZMMA-UHFFFAOYSA-N 0.000 claims 1
- OFGJEDCGQYUCMP-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CN(CCC1)C)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(CN(CCC1)C)=O)F OFGJEDCGQYUCMP-UHFFFAOYSA-N 0.000 claims 1
- UVBNEDJKFKWIGQ-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(COCCC1)=O)F UVBNEDJKFKWIGQ-UHFFFAOYSA-N 0.000 claims 1
- ZRUNJIRRNVPJRY-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(N(CCC1)C)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(N(CCC1)C)=O)F ZRUNJIRRNVPJRY-UHFFFAOYSA-N 0.000 claims 1
- BORGJBHLEUNCER-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(N(CCCC1)C)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(N(CCCC1)C)=O)F BORGJBHLEUNCER-UHFFFAOYSA-N 0.000 claims 1
- FAKRFSOILDGRAC-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1C(OCCCC1)=O)F FAKRFSOILDGRAC-UHFFFAOYSA-N 0.000 claims 1
- GKEIIGWFWVXVII-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCC(C1=O)(C)C)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCC(C1=O)(C)C)F GKEIIGWFWVXVII-UHFFFAOYSA-N 0.000 claims 1
- ZQZDHHANICHLRP-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)CC)NCCCN1CCOCCC1=O)F ZQZDHHANICHLRP-UHFFFAOYSA-N 0.000 claims 1
- VBWYTLXSZFXBHG-UHFFFAOYSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)CC)NCCCN1C(OCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)CC)NCCCN1C(OCCC1)=O)F VBWYTLXSZFXBHG-UHFFFAOYSA-N 0.000 claims 1
- SEPDDAMBQUORPN-OAQYLSRUSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@@H]2N(CC1)CCC2)CC)NCCCN1C(OCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@@H]2N(CC1)CCC2)CC)NCCCN1C(OCCC1)=O)F SEPDDAMBQUORPN-OAQYLSRUSA-N 0.000 claims 1
- MQXRMDFRUIXSEY-OYRHEFFESA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1C(OCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1C(OCCC1)=O)F MQXRMDFRUIXSEY-OYRHEFFESA-N 0.000 claims 1
- QZKVQOXKTHJDEN-SZPZYZBQSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1C(OCCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1C(OCCCC1)=O)F QZKVQOXKTHJDEN-SZPZYZBQSA-N 0.000 claims 1
- WULLAOAXCGUTIR-ZRZAMGCNSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1CCOCC(C1=O)(C)C)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2CC[C@@H](C1)N2C)CC)NCCCN1CCOCC(C1=O)(C)C)F WULLAOAXCGUTIR-ZRZAMGCNSA-N 0.000 claims 1
- SEPDDAMBQUORPN-NRFANRHFSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2N(CC1)CCC2)CC)NCCCN1C(OCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1C[C@H]2N(CC1)CCC2)CC)NCCCN1C(OCCC1)=O)F SEPDDAMBQUORPN-NRFANRHFSA-N 0.000 claims 1
- JKQBHJGKOLWXEO-WOJBJXKFSA-N FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1[C@H]2CN([C@@H](C1)C2)C)CC)NCCCN1C(OCCC1)=O)F Chemical compound FC(C=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1[C@H]2CN([C@@H](C1)C2)C)CC)NCCCN1C(OCCC1)=O)F JKQBHJGKOLWXEO-WOJBJXKFSA-N 0.000 claims 1
- IFPQOBROCLZSOZ-UHFFFAOYSA-N FC(OC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)F Chemical compound FC(OC1=C(C=CC(=C1)N1CCN(CC1)C)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)F IFPQOBROCLZSOZ-UHFFFAOYSA-N 0.000 claims 1
- TXSKQAODRAYIDW-UHFFFAOYSA-N FC1=C(C=CC(=C1)CCCN1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F Chemical compound FC1=C(C=CC(=C1)CCCN1CCOCC1)NC1=NC=C(C(=C1)NCCCN1C(OCCC1)=O)C(F)(F)F TXSKQAODRAYIDW-UHFFFAOYSA-N 0.000 claims 1
- ILQBWKKVDXUERZ-UHFFFAOYSA-N FCCN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C Chemical compound FCCN1CCN(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F)C ILQBWKKVDXUERZ-UHFFFAOYSA-N 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- SSVKWPBRBFCKJH-UHFFFAOYSA-N N1(CCNCCC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F Chemical compound N1(CCNCCC1)C1=CC=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CCCC1)=O)C(F)(F)F SSVKWPBRBFCKJH-UHFFFAOYSA-N 0.000 claims 1
- HQORIWOOAKPXHJ-UHFFFAOYSA-N N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F)CC Chemical compound N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(C(C1)(C)C)=O)C(F)(F)F)CC HQORIWOOAKPXHJ-UHFFFAOYSA-N 0.000 claims 1
- VSWQBEMQBBLHJF-UHFFFAOYSA-N N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F)CC Chemical compound N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1C(CC1)=O)C(F)(F)F)CC VSWQBEMQBBLHJF-UHFFFAOYSA-N 0.000 claims 1
- RMYQAISOHBVKNX-UHFFFAOYSA-N N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)F)CC Chemical compound N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCC(C1=O)(C)C)C(F)F)CC RMYQAISOHBVKNX-UHFFFAOYSA-N 0.000 claims 1
- CRTLEBFCZGNRKM-UHFFFAOYSA-N N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC Chemical compound N12CCN(C(CC1)C2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC CRTLEBFCZGNRKM-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- GJTCEEQWDPSDLY-BGYRXZFFSA-N [C@H]12CN(C[C@H](CC1)N2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC Chemical compound [C@H]12CN(C[C@H](CC1)N2)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)CC GJTCEEQWDPSDLY-BGYRXZFFSA-N 0.000 claims 1
- PUTOPDLWAMGKOV-RTBURBONSA-N [C@H]12OC[C@H](N(C1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C)C2 Chemical compound [C@H]12OC[C@H](N(C1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NCCCN1CCOCCC1=O)C(F)(F)F)C)C2 PUTOPDLWAMGKOV-RTBURBONSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Spoj predstavljen pomoću:
[image]
ili njegova farmaceutski prihvatljiva sol, enantiomer, stereoizomer, ili tautomer, pri čemu:
W je CH ili N;
X je CH ili N;
Y je C(R3) ili N;
R1 je odabrano iz grupe koja se sastoji od halogena, cijano, C1-C5alkila, i C3-C5cikloalkila, pri čemu svaki C1-C5alkil i C3-C5cikloalkil može biti opcionalno supstituiran sa jednim, dva ili tri nezavisna pojavljivanja fluora;
R2 je odabrano iz grupe koja se sastoji od H, halogena, cijano, C1-C5alkila, C3-C6cikloalkila, C2-C5alkenila, C2-C5alkinila, C1-C5alkoksi, i C1-C5alkoksi-C2-C5alkila, pri čemu svaki C1-C5alkil, C3-C6cikloalkil, C2-C5alkenil, C2-C5alkinil, i C1-C5alkoksi može biti opcionalno supstituiran sa jednim, dva ili tri nezavisna pojavljivanja fluora ili cijano;
svako pojavljivanje R3 i R33 je nezavisno odabrano iz grupe koja se sastoji od H, halogena, C1-C6alkila, i C1-C6alkoksi, pri čemu svaki C1-C6alkil i C1-C6alkoksi može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora;
R4 je odabrano iz grupe koja se sastoji od B, D, NR6R9, NR6-(C(R10)2)p-NR9R9, C(O)-NR6R9, C(O)-B, C(O)-D, i CN;
B je odabrano od N-vezanog heterociklila koji ima najmanje jedan dušik i koji opcionalno ima dodatni dušik ili kisik u prstenu i heteroaril, pri čemu B može biti opcionalno supstituirano na jednom ili više dostupnih ugljika sa R7 i može biti opcionalno supstituirano na dostupnom dušiku sa R9;
D je je odabrano od C-vezanog heterociklila koji ima najmanje jedan dušik i koji opcionalno ima dodatni dušik ili kisik u prstenu i heteroaril, pri čemu D može biti opcionalno supstituirano na jednom ili više dostupnih ugljika sa R7 i može biti opcionalno supstituirano na dostupnom dušiku sa R9;
svako pojavljivanje R7 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6alkila, C3-C6cikloalkila, cijano, i (C(R10)2)h-NR9R9, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora, ili dva R7 su spojena zajedno sa atomom za koji su vezana da formiraju okso;
svako pojavljivanje R6 i R9 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6alkila, C3-C6cikloalkila, C1-C5alkoksi-C2-C5alkila, C(=O)R5, SO2R5, i C-vezanog heterociklila koji ima najmanje jedan dušik i koji opcionalno ima dodatni dušik ili kisik u prstenu, i heteroaril, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora;
svako pojavljivanje R5 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6alkila, C3-C6cikloalkila, i heterociklila, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora;
svako pojavljivanje R10 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C3alkila, i C3-C5cikloalkila, pri čemu svaki C1-C3alkil i C3-C5cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora, ili dva R10 su spojena zajedno sa ugljikom za koji su vezani da formiraju C3-C5cikloalkil;
Z je odabrano iz grupe koja se sastoji od 4-očlanog laktamskog prstena vezanog preko atoma dušika i 6-10-očlanog laktamskog prstena vezanog preko atoma dušika, pri čemu atom laktamskog prstena može opcionalno biti kisik ili NR6 gde laktamski prsten je 6-10-očlani prsten i dostupan atom ugljika na 4-očlanom laktamskom prstenu ili 6-10-očlani laktamski prsten je opcionalno supstituiran sa R36,
svako pojavljivanje R36 je nezavisno odabrano od C1-C6alkila i C3-C6cikloalkila, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora, ili dva R36 su spojena zajedno sa ugljikom za koji su vezana da se formira C3-C6cikloalkil;
h je 1, 2, ili 3;
m je 0, 1, 2, ili 3;
n je 2, 3, ili 4; i
p je 2 ili 3;
pod uslovom da oba X i Y nisu N.
2. Spoj prema patentnom zahtjevu 1, pri čemu Z je odabrano od:
(i)
[image]
pri čemu
V je odabrano iz grupe koja se sastoji od kisika, C(R34)2, i NR6;
svako pojavljivanje R34 je nezavisno odabrano od H i R36, pri čemu svako pojavljivanje R36 je nezavisno odabrano od C1-C6alkila i C3-C6cikloalkila, ili dva R36 su spojena zajedno sa ugljikom za koji su vezana da formiraju C3-C6cikloalkil;
q je 0, 1, 2, ili 3; i
r je 2 ili 4;
pod uslovom da, ako q je 0, tada r nije 2; ili
(ii)
[image]
pri čemu
V je odabrano iz grupe koja se sastoji od kisika, C(R34)2, i NR6;
svako pojavljivanje R34 je nezavisno odabrano od H i R36, pri čemu svako pojavljivanje R36 je nezavisno odabrano od C1-C6alkila i C3-C6cikloalkila, ili dva R36 su spojena zajedno sa ugljikom za koji su vezana da formiraju C3-C6cikloalkil;
q je 0, 1, 2, ili 3; i
r je 2 ili 3;
pod uslovom da, ako q je 0, tada r nije 2, na primjer pri čemu Z je odabrano iz grupe koja se sastoji od
[image]
[image]
3. Spoj prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu:
R4 je odabrano iz grupe koja se sastoji od
[image]
[image]
[image]
[image]
pri čemu u je 1 ili 2; i/ili
R1 je odabrano iz grupe koja se sastoji od halogena, C1-C5alkila, i C3-C5cikloalkila, pri čemu C1-C5alkil može biti opcionalno supstituiran sa jednim, dva, ili tri pojavljivanja fluora; i/ili
R2 je odabrano iz grupe koja se sastoji od C1-2alkila, C3-4cikloalkila, kloro i bromo; i/ili
n je 3.
4. Spoj prema patentnom zahtjevu 1 predstavljen pomoću:
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
Z je odabrano iz grupe koja se sastoji od
[image]
[image]
R2 je odabrano iz grupe koja se sastoji od halogena, C1-C2alkila i C3-C4cikloalkila;
R4 je odabrano iz grupe koja se sastoji od
[image]
svako pojavljivanje R6 i R9 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6alkila, C3-C6cikloalkila, C(=O)R5, SO2R5, i C-vezanog heterociklila koji ima najmanje jedan dušik i koji opcionalno ima dodatni dušik ili kisik u prstenu, i heteroaril, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora;
svako pojavljivanje R7 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6 alkila, i C3-C6cikloalkila, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora, ili dva R7 su spojena zajedno sa atomom za koji su vezana da formiraju okso; i
svako pojavljivanje R34 je nezavisno odabrano od H i R36, pri čemu svako pojavljivanje R36 je nezavisno odabrano od C1-C6alkila i C3-C6cikloalkila, pri čemu svaki C1-C6alkil i C3-C6cikloalkil može biti opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora, ili dva R36 su spojena zajedno sa ugljikom za koji su vezana da formiraju C3-C6cikloalkil.
5. Spoj prema patentnom zahtjevu 4, pri čemu:
R1 je odabrano iz grupe koja se sastoji od halogena, C1-C5alkila, i C3-C5cikloalkila, pri čemu C1-C5alkil može biti opcionalno supstituiran sa jednim, dva ili tri pojavljivanja fluora, na primjer CF3; i/ili
R2 je odabrano iz grupe koja se sastoji od H, C3-C4cikloalkila, C1-C5alkila, i halogena; i/ili
R4 je odabrano iz grupe koja se sastoji od
[image]
i/ili
Z je odabrano iz grupe koja se sastoji od:
[image]
[image]
i
[image]
; i/ili
svako pojavljivanje R6 i R9 je nezavisno odabrano iz grupe koja se sastoji od H, C1-C6alkila, i C3-C6cikloalkila, pri čemu svaki od C1-C6alkila i C3-C6cikloalkila je opcionalno supstituiran sa jednim ili više nezavisnih pojavljivanja fluora.
6. Spoj prema patentnom zahtjevu 1 predstavljen pomoću:
(i)
[image]
pri čemu
R1 je odabrano iz grupe koja se sastoji od CF3, CF2H, bromo, kloro, i ciklopropila;
R2 je odabrano iz grupe koja se sastoji od C1-C2alkila, C3-C4cikloalkila, i halogena; i
R9 je odabrano iz grupe koja se sastoji od C1-C3alkila, H, i C3-C5cikloalkila; ili
(ii)
[image]
pri čemu
R1 je odabrano iz grupe koja se sastoji od bromo, kloro, CF3, CF2H, i ciklopropila;
R2 je odabrano iz grupe koja se sastoji od C1-C2alkila, C3-C4cikloalkila, i halogena; i
R9 je odabrano iz grupe koja se sastoji od C1-C3alkila, H, i C3-C5cikloalkila.
7. Spoj prema patentnom zahtjevu 6, pri čemu R1 je CF3; R2 je odabrano iz grupe koja se sastoji od C1-C2alkila, C3-C4cikloalkila, bromo, i kloro; i R9 je odabrano od C1-C3alkila i H.
8. Spoj prema patentnom zahtjevu 1 odabrano iz grupe koja se sastoji od 1-(3-((5-bromo-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-etilpiperazin-1-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-kloro-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-ciklopropil-4-(4-metil-1,4-diazepan-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-kloro-2-((2-metil-4-(1-metilpiperidin-4-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, (R)-1-(3-etil-4-((4-((3-(2-oksopiperidin-1-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)fenil)pirolidin-3-karbonitrila, 1-(3-((2-((4-(4-ciklopropilpiperazin-1-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-bromo-2-((2-izopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-etil-4-(4-etilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 4-(3-ciklopropil-4-((4-((3-(2-oksopiperidin-1-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)fenil)-1-metilpiperazin-2-ona, 1-(3-((5-bromo-2-((4-(4-etilpiperazin-1-il)-2-izopropilfenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-metil-4-(1-metilpiperidin-4-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-kloro-2-((4-(4-etilpiperazin-1-il)-2-izopropilfenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-ciklopropil-5-fluoro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-metil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-metil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-(2-fluoroetil)piperazin-1-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-kloro-2-((2-metil-4-(piperidin-4-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-acetilpiperazin-1-il)-2-ciklopropilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((5-kloro-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, (S)-1-(3-etil-4-((4-((3-(2-oksopiperidin-1-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)fenil)pirolidin-3-karbonitrila, 1-(3-((5-bromo-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-izopropilpiperazin-1-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-izopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-ciklobutilpiperazin-1-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3 -((2-((2-ciklopropil-4-(4-etilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-metil-4-(piperidin-4-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(1,4-diazepan-1 - il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3 -((2-((2-etil-4-(4-metil-1,4-diazepan-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-etilpiperazin-1-il)-2-izopropilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-(4-etil-1,4-diazepan-1-il)fenil) amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-metil-6-morfolinopiridin-3-il)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 3-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-kloro-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-bromo-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-ciklopropil-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-etil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-bromo-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-metil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, rac-(R)-3-(3-((2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5 - (trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, rac-(R)-3-(3-((2-((2-ciklopropil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-etil-4-(4-metil-2-oksopiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-metil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)morfolin-3-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azepan-2-ona, 4-(3-((2-((2-etil-4-morfolinofenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-morfolinofenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-kloro-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-kloro-2-((2-etil-4-morfolinofenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-kloro-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-kloro-2-((2-ciklopropil-4-morfolinofenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((4-(4-etilpiperazin-1-il)-2-izopropilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-ciklopropil-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3 -ona, 4-(3-((2-((2-etil-4-(4-metil-1,4-diazepan-1 - il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-5-fluoro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-bromo-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-bromo-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-bromo-2-((2-izopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-metil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-morfolinofenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-morfolinofenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((4-(4-etilpiperazin-1-il)-2-izopropilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-metil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-bromo-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, rac-4-(3-((2-((4-((1R,4R)-2-oksa-5-azabiciklo[2.2.1]heptan-5-il)-2-metilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(4-metil-1,4-diazepan-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-kloro-2-((2-etil-4-(4-metilpiperazin-1 -il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-bromo-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-kloro-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-ciklopropil-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-5-fluoro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-bromo-2-((2-izopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-kloro-2-((2-izopropil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1 ,4-oksazepan-5-ona, 4-(3-((5-kloro-2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, rac-(R)-4-(3-((2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5 -(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazinan-2-ona, 1-(3-((2-((4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((4-metil-6-(4-metilpiperazin-1-il)piridin-3-il)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 1-(3 -((2-((4-metil-6-morfolinopiridin-3-il)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 4-(3-((5-kloro-2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 1-(3-((2-((4-metil-6-(4-metilpiperazin-1-il)piridin-3-il)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((5-(4-metilpiperazin-1-il)piridin-2-il)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 4-(3-((2-((4-etil-6-(4-metilpiperazin-1-il)piridin-3-il)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((4-etil-6-(4-metilpiperazin-1-il)piridin-3-il)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, (R)-4-(3-((2-((2-ciklopropil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-((lS,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-etil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 4-(3-((2-((2-ciklopropil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-ciklopropil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 4-(3-((2-((2-etil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-etil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((4-etil-6-(4-metilpiperazin-1-il)piridin-3-il)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)pirimidin-5-karbonitrila, 3-(3-((2-((2-ciklopropil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1heptan-2-il)fenil)amino) -5 -(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, (4-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 4-(3-((2-((2-etil-4-(1-metilpiperidin-4-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-((1R,5S)-3-metil-3,8-diazabiciklo[3.2.1]oktan-8-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(9-metil-3,9-diazabiciklo[3.3.1]nonan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(3-metil-3,9-diazabiciklo[3.3.1]nonan-9-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(1-metilpirolidin-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etinil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-(etinil-d)-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-(etil-d5)-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((4-(4-metilpiperazin-1-il)-2-(2,2,2-trifluoroetil)fenil)amino) -5 -(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-(1,1-difluoroetil)-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 5-(4-metilpiperazin-1-il)-2-((4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)benzonitrila, 2-metil-2-(5-(4-metilpiperazin-1-il)-2-((4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)fenil)propannitrila, 2-(5-(4-metilpiperazin-1-il)-2-((4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)fenil)acetonitrila, 4-(3-((2-((4-(4-metilpiperazin-1-il)-2-(trifluorometil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-(difluorometil)-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-bromo-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-kloro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(3-((dimetilamino)metil)azetidin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 1-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3-metiltetrahidropirimidin-2(1H)-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3-metiltetrahidropirimidin-2(1H)-ona, 3-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 1-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-4-metil-1,4-diazepan-2-ona, 1-(3 -((2-((2-ciklopropil-4-(4-metilpiperazin-1 - il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-4-metil-1,4-diazepan-2-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1-metil-1,4-diazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1-metil-1,4-diazepan-5-ona, 1-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3-metil-1,3-diazepan-2-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3-metil-1,3-diazepan-2-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, (R)-3-(3-((5-(difluorometil)-2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, (S)-3-(3-((5-(difluorometil)-2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-(piperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 1-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-3-metiltetrahidropirimidin-2(1H)-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-3-metiltetrahidropirimidin-2(1H)-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 1-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-4-metil-1,4-diazepan-2-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-4-metil-1,4-diazepan-2-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-1-metil-1,4-diazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1-metil-1,4-diazepan-5-ona, 1-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-3-metil-1,3-diazepan-2-ona, 1-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-3-metil-1,3-diazepan-2-ona, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, (R)-2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, (S)-2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(piperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(piperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazinan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-metil-2-oksotetrahidropirimidin-1(2H)-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-metil-2-oksotetrahidropirimidin-1(2H)-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-okso-1,4-oksazepan-4-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-okso-1,4-oksazepan-4-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazepan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(2-okso-1,3-oksazepan-3-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(4-metil-2-okso-1,4-diazepan-1-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(4-metil-7-okso-1,4-diazepan-1-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(4-metil-7-okso-1,4-diazepan-1-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-metil-2-okso-1,3-diazepan-1-il)propil)amino)pirimidin-5-karbonitrila, 2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-4-((3-(3-metil-2-okso-1,3-diazepan-1-il)propil)amino)pirimidin-5-karbonitrila, 1-(3-((2-((2-ciklopropil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3 -((2-((2-ciklopropil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 3-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,3-oksazinan-2-ona, 4-(3-((2-((2-ciklopropil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-((1R,SS)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3 -ona, 4-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 3-(3-((5-(difluorometil)-2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 3-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazepan-2-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 3-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,3-oksazinan-2-ona, 4-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-2,2-dimetil-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-2,2-dimetil-1,4-oksazepan-3-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 8-(3-((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-5-oksa-8-azaspiro[2.6]nonan-9-ona, 4-(3-((2-((4-(1,4-diazabiciklo[3.2.1]oktan-4-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 4-(3-((5-(difluorometil)-2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 4-(3-((2-((4-(1,4-diazabiciklo[3.2.1]oktan-4-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 4-(3-((2-((4-(1,4-diazabiciklo[3.2.1]oktan-4-il)-2-etilfenil)amino)-5-(difluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,4-oksazepan-5-ona, 1-(3-((2-((2-etil-4-(4-metilpiperazin-1 -il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azetidin-2-ona, 1-(3 -((2-((2-etil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3,3-dimetilazetidin-2-ona, 1-(3-((2-((4-(1,4-diazabiciklo[3.2.1]oktan-4-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azetidin-2-ona, 1-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azetidin-2-ona, 1-(3-((2-((2-etil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3,3-dimetilazetidin-2-ona, 1-(3-((2-((4-(1,4-diazabiciklo[3.2.1]oktan-4-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3,3-dimetilazetidin-2-ona, 1-(3-((2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azetidin-2-ona, 1-(3 -((2-((2-etil-4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3,3-dimetilazetidin-2-ona, 1-(3-((2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azetidin-2-ona, 1-(3-((2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-3,3-dimetilazetidin-2-ona, 1-(3-((2-((2-etil-4-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)pirolidin-2-ona, 4-(3-((2-((4-(3-(dietilamino)propil)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-ciklopropil-4-(3-morfolinopropil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 3-(3-((2-((2-etil-4-(2-(pirolidin-1-il)etil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-((dimetilamino)metil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-karbonil)fenil)amino)-5 -(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-metoksi-N-(1-metilpiperidin-4-il)-4-((4-((3-(5-okso-1,4-oksazepan-4-il)propil)amino)-5-(trifluorometil)pirimidin-2-il)amino)benzamida, 1-(3-((2-((2-ciklopropil-4-(morfolinometil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 1-(3-((2-((2-etil-4-(2-(pirolidin-1-il)propan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 4-(3-((2-((2-etil-4-(2-(4-metilpiperazin-1-il)-2-oksoetil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((4-(4-((dimetilamino)metil)piperidin-1-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((4-(3,3-dimetilpiperazin-1-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-4-(3,3,5,5-tetrametilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-ciklopropil-4-(3,4,5-trimetilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-etil-4-(3,3,4-trimetilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-etil-4-(3,3,4,5,5-pentametilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 1-(3-((2-((2-kloro-4-(3,4-dimetilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)azepan-2-ona, 3-(3-((2-((4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazepan-2-ona, 4-(3-((2-((4-(heksahidropirolo[1,2-a]pirazin-2(1H)-il)fenil)amino)-5 -(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((4-(oktahidro-2H-pirido[1,2-a]pirazin-2-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-3-ona, 3-(3-((2-((4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazepan-2-ona, 4-(3-((2-((4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((4-(5-metil-2,5-diazabiciklo [2.2.1heptan-2-il)fenil)amino) -5 -(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-bromo-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazepan-2-ona, 4-(3-((2-((2-metil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((6-(5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)piridin-3-il)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 1-(3-((2-((4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)azepan-2-ona, 4-(3-((2-((4-(4-metilpiperazin-1-il)-2-(trifluorometil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-metil-4-(4-(metilsulfonil)piperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-etil-4-(4-metilpiperazin-1-karbonil)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 1-(3-((2-((2-ciklopropil-4-(morfolinometil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 3-(3-((2-((2-etil-4-(2-(pirolidin-1-il)etil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-fluoro-4-(3-morfolinopropil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazinan-2-ona, 1-(3-((2-((2-ciklopropil-4-((1,1-dioksidotiomorfolino)metil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)piperidin-2-ona, 3-(3-((2-((4-(3-(dietilamino)propil)-2-(trifluorometil)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,3-oksazinan-2-ona, 4-(3-((2-((2-kloro-4-(3,4-dimetilpiperazin-1-il)fenil)amino)-5-(trifluorometil)piridin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-metil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-kloro-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-metil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-kloro-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-metil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-kloro-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-kloro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-kloro-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-metil-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-kloro-4-((1S,4S)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-metil-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 3-(3-((2-((2-kloro-4-((1R,4R)-5-metil-2,5-diazabiciklo[2.2.1]heptan-2-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,3-oksazinan-2-ona, 4-(3-((2-((2-metil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-kloro-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-metil-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((2-kloro-4-((1R,5S)-8-metil-3,8-diazabiciklo[3.2.1]oktan-3-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-3-ona, 4-(3-((2-((4-(4-metilpiperazin-1-il)-2-(trifluorometoksi)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((2-(difluorometoksi)-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 3-(3-((2-((2-ciklopropil-4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-6,6-dimetil-1,3-oksazinan-2-ona, 4-(3-((2-((4-((1R,5S)-3,8-diazabiciklo[3.2.1]oktan-3-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 1-(3-((2-((2-ciklopropil-4-(3-((dimetilamino)metil)azetidin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)piperidin-2-ona, 4-(3-((2-((4-(3-((dimetilamino)metil)azetidin-1-il)-2-etilfenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, 4-(3-((2-((4-(4-metilpiperazin-1-il)fenil)amino)-5-(trifluorometil)pirimidin-4-il)amino)propil)-1,4-oksazepan-5-ona, i njihovih farmaceutski prihvatljivih soli, enantiomera, stereoizomera, i tautomera.
9. Spoj prema patentnom zahtjevu 1 odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i farmaceutski prihvatljive soli istog, na primjer pri čemu je spoj predstavljen pomoću:
(i)
[image]
ili farmaceutski prihvatljive soli istog;
(ii)
[image]
ili farmaceutski prihvatljive soli istog; ili
(iii)
[image]
ili farmaceutski prihvatljive soli istog.
10. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1-9, farmaceutski prihvatljiv ekscipijens i opcionalno jedan ili više dodatnih terapijskih agenasa.
11. Farmaceutska kompozicija prema patentnom zahtjevu 10, pri čemu dodatni terapijski agens je prisutan i on je (i) inhibitor MAPKAP puta, na primjer MEK inhibitor kao što je MEK inhibitor odabran iz grupe koja se sastoji od trametiniba, selumetiniba, kobimetiniba, binimetiniba, i farmaceutski prihvatljivih soli istog; ERK inhibitor kao što je ERK inhibitor odabran iz grupe koja se sastoji od uliksertiniba, SCH772984, LY3214996, ravoksertiniba, VX-11e, i farmaceutski prihvatljivih soli istog; RAF inhibitor kao što je RAF inhibitor odabran iz grupe koja se sastoji od LY3009120, LXH254, RAF709, dabrafeniba, vemurafeniba, i farmaceutski prihvatljivih soli istog; ili Ras inhibitor, kao što je Ras inhibitor odabran iz grupe koja se sastoji od AMG-510, MRTX849, i farmaceutski prihvatljivih soli istog; ili (ii) hemioterapijski agens, kao što je hemioterapijski agens odabran iz grupe koja se sastoji od anti-tubulinskog agensa, vinorelbina, DNK-alkilirajućih agenasa, DNK interkalirajućih agenasa, 5-fluorouracila, kapecitabina, citarabina, decitabina, 5-aza citadina, gemcitabina, i metotreksata.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-9 za primjenu u liječenju poremećaja kod pacijenta koji za tim ima potrebu.
13. Spoj prema bilo kojem od patentnih zahtjeva 1-9 za primjenu u postupku liječenja raka kod pacijenta koji za tim ima potrebu, koji obuhvaća administriranje pacijentu terapijski efektivne količine spoja.
14. Spoj za primjenu prema patentnom zahtjevu 13, pri čemu je rak odabran iz grupe koja se sastoji od gastrointestinalnih stromalnih tumora, raka jednjaka, raka želuca, melanoma, glioma, glioblastoma, raka jajnika, raka mokraćnog mjehura, raka gušterače, raka prostate, raka pluća, raka dojke, raka bubrega, raka jetre, osteosarkoma, multiplih mijeloma, cervikalnih karcinoma, raka koji metastaziraju na kost, papilarnog tiroidnog karcinoma, raka pluća nemalih stanica, i kolorektalnih karcinoma.
15. Spoj za primjenu prema patentnom zahtjevu 13 ili patentnom zahtjevu 14, pri čemu postupak dalje obuhvaća administriranje pacijentu jednog ili više dodatnih terapijskih agenasa, na primjer pri čemu dodatni terapijski agens je (i) inhibitor MAPKAP puta, na primjer MEK inhibitor, kao što je MEK inhibitor odabran iz grupe koja se sastoji od trametiniba, selumetiniba, kobimetiniba, binimetiniba, i farmaceutski prihvatljivih soli istog; ERK inhibitor kao što je ERK inhibitor odabran iz grupe koja se sastoji od uliksertiniba, SCH772984, LY3214996, ravoksertiniba, VX-11e, i farmaceutski prihvatljivih soli istog; RAF inhibitor kao što je RAF inhibitor odabran iz grupe koja se sastoji od LY3009120, LXH254, RAF709, dabrafeniba, vemurafeniba, i farmaceutski prihvatljivih soli istog; ili Ras inhibitor, kao što je Ras inhibitor odabran iz grupe koja se sastoji od AMG-510, MRTX849, i farmaceutski prihvatljivih soli istog; ili (ii) hemioterapijski agens, kao što je hemioterapijski agens odabran iz grupe koja se sastoji od anti-tubulinskih agenasa, vinorelbina, DNK-alkilirajućih agenasa, DNK interkalirajućih agenasa, 5-fluorouracila, kapecitabina, citarabina, decitabina, 5-aza citadina, gemcitabina, i metotreksata.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846258P | 2019-05-10 | 2019-05-10 | |
US201962846251P | 2019-05-10 | 2019-05-10 | |
US201962911730P | 2019-10-07 | 2019-10-07 | |
US201962911728P | 2019-10-07 | 2019-10-07 | |
EP20729420.8A EP3966207B1 (en) | 2019-05-10 | 2020-05-08 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
PCT/US2020/032087 WO2020231806A1 (en) | 2019-05-10 | 2020-05-08 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231730T1 true HRP20231730T1 (hr) | 2024-05-10 |
Family
ID=73046797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231730TT HRP20231730T1 (hr) | 2019-05-10 | 2020-05-08 | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
Country Status (25)
Country | Link |
---|---|
US (2) | US11530206B2 (hr) |
EP (2) | EP3966207B1 (hr) |
JP (1) | JP2022531801A (hr) |
KR (1) | KR20220008873A (hr) |
CN (1) | CN114127057A (hr) |
AU (2) | AU2020275392B2 (hr) |
BR (1) | BR112021022504A2 (hr) |
CA (1) | CA3139708A1 (hr) |
CL (1) | CL2021002952A1 (hr) |
CO (1) | CO2021016768A2 (hr) |
DK (1) | DK3966207T3 (hr) |
ES (1) | ES2966807T3 (hr) |
FI (1) | FI3966207T3 (hr) |
HR (1) | HRP20231730T1 (hr) |
IL (1) | IL287787A (hr) |
LT (1) | LT3966207T (hr) |
MX (1) | MX2021013661A (hr) |
PE (1) | PE20220597A1 (hr) |
PL (1) | PL3966207T3 (hr) |
PT (1) | PT3966207T (hr) |
RS (1) | RS65019B1 (hr) |
SG (1) | SG11202112336PA (hr) |
SI (1) | SI3966207T1 (hr) |
TW (1) | TW202108573A (hr) |
WO (1) | WO2020231806A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
HRP20231478T1 (hr) | 2018-12-28 | 2024-04-26 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitori za primjenu u liječenju raka |
JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
RS64755B1 (sr) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
KR20220024605A (ko) | 2019-06-17 | 2022-03-03 | 데시페라 파마슈티칼스, 엘엘씨. | 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
EP4076418A4 (en) | 2019-12-20 | 2024-01-24 | Mirati Therapeutics Inc | SOS1 INHIBITORS |
CN115243681A (zh) | 2019-12-30 | 2022-10-25 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
LT4084778T (lt) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai |
WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
CN117545751A (zh) * | 2021-04-07 | 2024-02-09 | 生命爱科 | 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途 |
WO2023087027A1 (en) * | 2021-11-15 | 2023-05-19 | Erasca, Inc. | Thiophene ulk1/2 inhibitors and their use thereof |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024050351A1 (en) * | 2022-09-02 | 2024-03-07 | Deciphera Pharmaceuticals, Llc | Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer |
WO2024099225A1 (zh) * | 2022-11-08 | 2024-05-16 | 微境生物医药科技(上海)有限公司 | Ulk抑制剂 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
EP1438053B1 (de) | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
CN1717396A (zh) * | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途 |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
CN100549014C (zh) | 2003-07-16 | 2009-10-14 | 詹森药业有限公司 | 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物 |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
UA92150C2 (ru) | 2004-06-04 | 2010-10-11 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
JP5369257B2 (ja) | 2006-02-15 | 2013-12-18 | アッヴィ・インコーポレイテッド | 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用 |
BRPI0711628A2 (pt) | 2006-05-15 | 2011-12-06 | Irm Llc | composto, composição farmacêutica, uso e processo para preparação do composto |
US20070293494A1 (en) | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
CN101611035A (zh) | 2006-12-28 | 2009-12-23 | 大正制药株式会社 | 吡唑并嘧啶化合物 |
US8143293B2 (en) | 2007-04-20 | 2012-03-27 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases |
JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
AU2009308853A1 (en) | 2008-10-29 | 2010-05-06 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
AU2011245248B2 (en) | 2010-04-29 | 2016-01-07 | Deciphera Pharmaceuticals, Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
MX2014006126A (es) | 2011-11-22 | 2015-03-19 | Deciphera Pharmaceuticals Llc | Amidas de piridona y analogos que exhiben actividades anticancerigenas y antiproliferativas. |
JP6117816B2 (ja) | 2011-11-29 | 2017-04-19 | ジェネンテック, インコーポレイテッド | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
CN104093426B (zh) | 2011-11-30 | 2019-06-28 | 健泰科生物技术公司 | 用于lrrk2的正电子发射体层摄影(pet)成像的氟-18和碳-11标记的放射性配体 |
WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
WO2014145015A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145029A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145023A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
SG11201507660TA (en) | 2013-03-15 | 2015-10-29 | Deciphera Pharmaceuticals Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9382228B2 (en) | 2013-03-15 | 2016-07-05 | Deciphera Pharmaceuticals, Llc | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145004A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
CA2917667A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
BR112016005881A2 (pt) | 2013-09-18 | 2017-09-12 | Beijing Hanmi Pharmaceutical Co Ltd | composto, composição farmacêutica e uso do composto |
CN104262328B (zh) | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
MY184733A (en) | 2013-10-18 | 2021-04-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
SG11201602387RA (en) | 2013-10-21 | 2016-05-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
US10266549B2 (en) | 2014-08-25 | 2019-04-23 | Salk Institute For Biological Studies | ULK1 inhibitors and methods using same |
US10336734B2 (en) | 2015-08-02 | 2019-07-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
US10738016B2 (en) | 2015-10-13 | 2020-08-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-kinase inhibitors as cancer therapeutics |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
CA3054809A1 (en) | 2017-02-28 | 2018-09-07 | The General Hospital Corporation | Uses of pyrimidopyrimidinones as sik inhibitors |
US20200129489A1 (en) | 2017-05-30 | 2020-04-30 | Deciphera Pharmaceuticals, Llc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
KR20200115606A (ko) | 2018-01-31 | 2020-10-07 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
KR20200143709A (ko) | 2018-04-10 | 2020-12-24 | 뉴로포레 테라피스, 인코포레이티드 | Pi3-키나제 및 오토파지 경로의 조절인자로서의 트리-치환된 아릴 및 헤테로아릴 유도체 |
HRP20231478T1 (hr) | 2018-12-28 | 2024-04-26 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitori za primjenu u liječenju raka |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
RS64755B1 (sr) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
KR20220024605A (ko) | 2019-06-17 | 2022-03-03 | 데시페라 파마슈티칼스, 엘엘씨. | 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
-
2020
- 2020-05-08 US US16/870,384 patent/US11530206B2/en active Active
- 2020-05-08 SI SI202030312T patent/SI3966207T1/sl unknown
- 2020-05-08 EP EP20729420.8A patent/EP3966207B1/en active Active
- 2020-05-08 ES ES20729420T patent/ES2966807T3/es active Active
- 2020-05-08 PT PT207294208T patent/PT3966207T/pt unknown
- 2020-05-08 KR KR1020217040559A patent/KR20220008873A/ko active Search and Examination
- 2020-05-08 PL PL20729420.8T patent/PL3966207T3/pl unknown
- 2020-05-08 FI FIEP20729420.8T patent/FI3966207T3/fi active
- 2020-05-08 PE PE2021001870A patent/PE20220597A1/es unknown
- 2020-05-08 WO PCT/US2020/032087 patent/WO2020231806A1/en active Application Filing
- 2020-05-08 CA CA3139708A patent/CA3139708A1/en active Pending
- 2020-05-08 HR HRP20231730TT patent/HRP20231730T1/hr unknown
- 2020-05-08 JP JP2021566469A patent/JP2022531801A/ja active Pending
- 2020-05-08 TW TW109115468A patent/TW202108573A/zh unknown
- 2020-05-08 CN CN202080049700.3A patent/CN114127057A/zh active Pending
- 2020-05-08 AU AU2020275392A patent/AU2020275392B2/en active Active
- 2020-05-08 MX MX2021013661A patent/MX2021013661A/es unknown
- 2020-05-08 SG SG11202112336PA patent/SG11202112336PA/en unknown
- 2020-05-08 BR BR112021022504A patent/BR112021022504A2/pt unknown
- 2020-05-08 RS RS20231266A patent/RS65019B1/sr unknown
- 2020-05-08 EP EP23206773.6A patent/EP4342469A2/en active Pending
- 2020-05-08 LT LTEPPCT/US2020/032087T patent/LT3966207T/lt unknown
- 2020-05-08 DK DK20729420.8T patent/DK3966207T3/da active
-
2021
- 2021-11-02 IL IL287787A patent/IL287787A/en unknown
- 2021-11-09 CL CL2021002952A patent/CL2021002952A1/es unknown
- 2021-12-10 CO CONC2021/0016768A patent/CO2021016768A2/es unknown
-
2022
- 2022-06-06 US US17/833,272 patent/US20230039712A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251416A patent/AU2023251416A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021013661A (es) | 2022-03-11 |
PE20220597A1 (es) | 2022-04-22 |
FI3966207T3 (fi) | 2023-11-30 |
AU2020275392B2 (en) | 2023-09-14 |
JP2022531801A (ja) | 2022-07-11 |
PT3966207T (pt) | 2023-12-20 |
CN114127057A (zh) | 2022-03-01 |
LT3966207T (lt) | 2023-12-11 |
IL287787A (en) | 2022-01-01 |
EP4342469A2 (en) | 2024-03-27 |
CA3139708A1 (en) | 2020-11-19 |
AU2023251416A1 (en) | 2023-11-09 |
US11530206B2 (en) | 2022-12-20 |
WO2020231806A1 (en) | 2020-11-19 |
BR112021022504A2 (pt) | 2022-04-12 |
CL2021002952A1 (es) | 2022-07-15 |
ES2966807T3 (es) | 2024-04-24 |
DK3966207T3 (da) | 2023-12-18 |
KR20220008873A (ko) | 2022-01-21 |
CO2021016768A2 (es) | 2022-04-08 |
RS65019B1 (sr) | 2024-01-31 |
PL3966207T3 (pl) | 2024-03-04 |
EP3966207B1 (en) | 2023-11-01 |
US20200354352A1 (en) | 2020-11-12 |
AU2020275392A1 (en) | 2021-12-02 |
SI3966207T1 (sl) | 2023-12-29 |
TW202108573A (zh) | 2021-03-01 |
EP3966207A1 (en) | 2022-03-16 |
SG11202112336PA (en) | 2021-12-30 |
US20230039712A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231730T1 (hr) | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene | |
HRP20231310T1 (hr) | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene | |
JPWO2020231806A5 (hr) | ||
RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
JP2018500376A5 (hr) | ||
HRP20180080T1 (hr) | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze | |
JP2019535664A5 (hr) | ||
ES2561277T3 (es) | Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas | |
RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20191936T1 (hr) | Biciklički spojevi kao inhibitori proizvodnje autotaksina (atx) i lizofosfatidne kiseline (lpa) | |
JP5823518B2 (ja) | ブルトン型チロシンキナーゼの阻害剤 | |
HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
JP2019517596A5 (hr) | ||
HRP20151133T1 (hr) | Tvari za smanjivanje stvaranja beta-amiloida | |
JP2018507861A5 (hr) | ||
HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
JP2021506923A5 (hr) | ||
JP2020505454A5 (hr) | ||
HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
RU2018123779A (ru) | Новые соединения | |
RU2012152548A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
HRP20230086T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
JP2021506858A5 (hr) | ||
JP2014521711A5 (hr) |